Personal information

No personal information available

Activities

Collapse all

Works (4)

Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial

European Heart Journal
2024-04-01 | Journal article
DOI: 10.1093/eurheartj/ehad889
Contributors: Neila Sayah; Deepak L Bhatt; Michael Miller; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Lixia Jiao; Armando Lira Pineda; Ralph T Doyle, Jr.; Jean Claude Tardif et al.
Source: check_circle
Crossref

Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE‐IT

Journal of the American Heart Association
2023-03-07 | Journal article
DOI: 10.1161/JAHA.121.026756
Contributors: Brian Olshansky; Deepak L. Bhatt; Michael Miller; Ph. Gabriel Steg; Eliot A. Brinton; Terry A. Jacobson; Steven B. Ketchum; Ralph T. Doyle, Jr; Rebecca A. Juliano; Lixia Jiao et al.
Source: check_circle
Crossref

Treatment With Icosapent Ethyl to Reduce Ischemic Events in Patients With Prior Percutaneous Coronary Intervention: Insights From REDUCE‐IT PCI

Journal of the American Heart Association
2022-03-15 | Journal article
DOI: 10.1161/JAHA.121.022937
Contributors: Benjamin E. Peterson; Deepak L. Bhatt; Ph. Gabriel Steg; Michael Miller; Eliot A. Brinton; Terry A. Jacobson; Steven B. Ketchum; Rebecca A. Juliano; Lixia Jiao; Ralph T. Doyle, Jr. et al.
Source: check_circle
Crossref

REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results

European Heart Journal - Cardiovascular Pharmacotherapy
2021-05-23 | Journal article
DOI: 10.1093/ehjcvp/pvaa118
Contributors: Brian Olshansky; Deepak L Bhatt; Michael Miller; Ph. Gabriel Steg; Eliot A Brinton; Terry A Jacobson; Steven B Ketchum; Ralph T Doyle Jr; Rebecca A Juliano; Lixia Jiao et al.
Source: check_circle
Crossref
How many people are using ORCID?